Bleeding and clot risk in new acute leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a new score (SiAML) to predict bleeding and blood clot risks in people newly diagnosed with acute leukemia. It aims to help doctors better manage these risks compared to current tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute leukemia (ALL, APL, or AML).
- You must not have a known blood clotting disorder passed down in your family.
- You must not have taken any antiplatelet drugs (like aspirin) or blood thinners (like warfarin) before your leukemia diagnosis.
- You must not have had bleeding caused by a known clotting problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at markers in the blood to understand why low red blood cell counts (anemia) can cause bleeding problems in people with certain leukemias. It may help find better ways to treat or prevent bleeding during early chemotherapy.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
This study looks at how blood counts and clotting change in adults newly diagnosed with acute myeloid leukemia (AML) who receive a strong type of chemotherapy. It aims to better understand how to manage these patients during treatment.
This trial looks at how a simple blood test (CRP to Albumin ratio) relates to blood clotting problems in people newly diagnosed with Acute Myeloid Leukemia (AML). The goal is to better understand how the disease affects your body and find ways to monitor your health.
This study looks at blood clotting problems in children with acute lymphoblastic leukemia (ALL) who are being treated with the ALLTogether1 protocol. It aims to understand how the disease and its treatment affect clotting, which could help improve care.
This study looks at two simple blood test markers (fibrinogen and albumin) to see if their ratio can help predict outcomes in people with newly diagnosed acute leukemia. It is a no-treatment study — just a blood draw at diagnosis to gather information.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.